Navigation Links
SPX to Acquire e&e, a Global Supplier of Extraction, Evaporation, Vacuum and Freeze Drying Technologies
Date:10/21/2011

CHARLOTTE, N.C., Oct. 21, 2011 /PRNewswire/ -- SPX Corporation (NYSE: SPW) today announced that its Flow Technology segment entered into a definitive agreement to acquire e&e Verfahrenstechnik GmbH (e&e), a leading supplier of extraction, evaporation, vacuum and freeze drying technologies to the global food and beverage, pharmaceutical and bioenergy industries.  The terms of the transaction were not disclosed.  The transaction is subject to customary closing conditions and is expected to be completed in the fourth quarter of 2011.

Founded in 1998 and based in Warendorf, Germany, e&e has approximately 40 employees and global capabilities through its commercial representation and sales in China, France, India, Indonesia, Japan, the Philippines, Russia, Turkey and Vietnam.  The company's extraction, evaporation, vacuum and freeze drying technologies are used primarily by customers in the food and beverage industry, but also by the pharmaceutical and bioenergy industries.

e&e has extensive in-house process and product expertise, and has developed production plants handling more than 300 different types of products.  A key market segment for the company is providing state-of-the-art processing technology for the soluble (instant) coffee industry, where e&e specializes in coffee extract preparation and freeze drying of coffee extract.

"Our acquisition of e&e will expand and enhance our food and beverage capabilities, and complement our 2010 acquisition of Anhydro, another leader in dry powder processing technologies and systems," said Don Canterna, segment president, SPX Flow Technology.  "Additionally, e&e's freeze drying technologies and deep experience in creating instant coffee production facilities will give expanded presence in the global coffee market, particularly in Europe and Asia, where e&e has strong relationships."

e&e's core technology covers solid/liquid and liquid/liquid extraction, thermal liquid concentration, solvent rectification, and vacuum/freeze continuous belt or tray drying of pharmaceutical extracts, coffee extract, herbal extract, instant tea extract and Traditional Chinese Medicine (TCM).  e&e also operates a test center for refining customer-specific processes and new product development.  The e&e test center enables the company to adapt and refine specific processes for its customers' needs for specific products, and helps facilitate the custom design and building of facilities to produce these products.

About SPX

Based in Charlotte, North Carolina, SPX Corporation (NYSE: SPW) is a global Fortune 500 multi-industry manufacturing leader with more than $5 billion in annual revenue, operations in more than 35 countries and approximately 16,000 employees.  The company's highly-specialized, engineered products and technologies serve customers in three primary strategic growth markets: infrastructure, process equipment and diagnostic tools.  Many of SPX's innovative solutions are playing a role in helping to meet rising global demand, particularly in emerging markets, for electricity, processed foods and beverages and vehicle services.  The company's products include thermal heat transfer equipment for power plants; power transformers for utility companies; process equipment for the food & beverage industry; and diagnostic tools and equipment for the vehicle service industry.  For more information, please visit http://www.spx.com/.

Certain statements in this press release including any statements relating to fulfillment of the terms of the referenced agreement, may be forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and are subject to the safe harbor created thereby.  Please refer to our public filings for a discussion of certain important factors that relate to forward-looking statements contained in this press release.  The word "expect," "believe" and similar expressions may identify forward-looking statements. Although the company believes that the expectations reflected in its forward-looking statements are reasonable, it can give no assurance that such expectations will prove to be correct.  Statements in the press release speak only as of the date of this press release, and SPX disclaims any responsibility to update or revise such statements.


'/>"/>
SOURCE SPX Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
2. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
3. Image Solutions, Inc. Acquires Zurich Biostatistics, Inc.
4. New Data Show Doripenem as Effective as Commonly Used Therapies in Treating Hospital-Acquired Pneumonias
5. U.S. Preventive Medicine Acquires Specialty Disease Management
6. MacroChem Acquires Rights to Pexiganan, a Novel Topical Anti-Infective for Treatment of Diabetic Foot Infections, From Genaera
7. FDA Accepts Wyeths Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
8. Nastech Reacquires Teriparatide (Parathyroid Hormone; PTH1-34) Nasal Spray from Procter & Gamble
9. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
10. Enanta Reports New Macrolide-Related Drug Class, Bicyclolides, to Combat Hospital and Community Acquired Superbug Infections, Including MRSA
11. Intercell AG to Acquire Iomai Corporation to Expand Late Stage Product Pipeline and Strengthen Leadership in Vaccine Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/7/2017)... 7, 2017 Diplomat Pharmacy, Inc. (NYSE: ... as president, effective Aug. 7, 2017. ... to pursue other interests and will serve as president emeritus ... has served us in multiple leadership roles since he joined ... 2015 and has provided decisive, strategic leadership which continues to ...
(Date:8/3/2017)... -- Opioid addiction and other drugs of abuse, blood poisoning ... outcomes, were problems taken on directly as laboratory professionals, ... them, met this week. This according to Kalorama Information. ... abuse, procalcitonin and acute kidney injury were key focuses ... in San Diego, CA.  Mechanisms ...
(Date:8/1/2017)... CerSci Therapeutics , a non-opioid drug development firm based ... notice from the National Institute on Drug Abuse (NIDA) ... has been awarded a Direct-to-Phase II Small Business Innovation ... an additional $1,000,000 to follow in 2018. These funds ... lead non-opioid drug candidate CT-044 to the Food and ...
Breaking Medicine Technology:
(Date:8/16/2017)... ... August 16, 2017 , ... TopConsumerReviews.com recently gave a best-in-class 5 ... , The healthcare industry in the United States has undergone major changes over the ... needing to have a doctor’s order to get a blood test or other lab ...
(Date:8/16/2017)... ... August 16, 2017 , ... Women’s Excellence in ... pain. In addition to oncology services, the new center will specialize in ... heavy bleeding during menstruation), uterine fibroids, and uterine and pelvic adhesions (scar tissue). ...
(Date:8/16/2017)... ... August 16, 2017 , ... Rollon Skin ... anti-aging skincare solutions, recently announced the launch of two new skincare products, Prache ... effective alternative to expensive plastic surgery or in-patient cosmetic dermatological procedures. , “Prache ...
(Date:8/16/2017)... ... ... Chain”: an inspirational story for those shackled by the chains of a broken life. ... writer and a woman of great faith and wisdom. She is a great motivational ... born and raised in Vero Beach, Florida and has dedicated her life and ministry to ...
(Date:8/15/2017)... (PRWEB) , ... August 15, 2017 , ... ... of disease. It’s reaching out to a patient who feels isolated. It’s developing ... amid madness. , WesternU President Daniel R. Wilson, MD, PhD, invited three renowned ...
Breaking Medicine News(10 mins):